Beverly Hills Private Wealth LLC Makes New Investment in Koninklijke Philips (NYSE:PHG)

Beverly Hills Private Wealth LLC bought a new position in Koninklijke Philips (NYSE:PHG) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 9,868 shares of the technology company’s stock, valued at approximately $230,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Citigroup Inc. increased its holdings in Koninklijke Philips by 1.3% in the 1st quarter. Citigroup Inc. now owns 36,882 shares of the technology company’s stock worth $1,126,000 after purchasing an additional 483 shares in the last quarter. Advisory Services Network LLC increased its holdings in Koninklijke Philips by 28.7% in the 1st quarter. Advisory Services Network LLC now owns 2,226 shares of the technology company’s stock worth $41,000 after purchasing an additional 496 shares in the last quarter. 1832 Asset Management L.P. increased its holdings in Koninklijke Philips by 1.1% in the 1st quarter. 1832 Asset Management L.P. now owns 56,735 shares of the technology company’s stock worth $1,708,000 after purchasing an additional 619 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its holdings in Koninklijke Philips by 3.2% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 22,616 shares of the technology company’s stock worth $451,000 after purchasing an additional 696 shares in the last quarter. Finally, Holderness Investments Co. increased its holdings in Koninklijke Philips by 4.4% in the 2nd quarter. Holderness Investments Co. now owns 16,507 shares of the technology company’s stock worth $358,000 after purchasing an additional 697 shares in the last quarter. Institutional investors and hedge funds own 13.67% of the company’s stock.

Koninklijke Philips Trading Down 0.4 %

Shares of PHG stock opened at $20.33 on Wednesday. The stock has a 50-day moving average of $20.40 and a 200-day moving average of $20.86. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.20 and a quick ratio of 0.78. Koninklijke Philips has a 1-year low of $17.75 and a 1-year high of $24.27.

Koninklijke Philips (NYSE:PHG) last announced its earnings results on Monday, January 29th. The technology company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.41 by $0.03. Koninklijke Philips had a positive return on equity of 14.17% and a negative net margin of 2.53%. The company had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.47 billion. As a group, analysts expect that Koninklijke Philips will post 1.53 earnings per share for the current year.

Analyst Upgrades and Downgrades

PHG has been the subject of several recent research reports. StockNews.com raised Koninklijke Philips from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. BNP Paribas cut Koninklijke Philips from an “outperform” rating to an “underperform” rating in a research note on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Koninklijke Philips presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.00.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.